Picture supply: Getty Photographs
The Protect Therapeutics (LSE:STX) share value has rocketed within the final 12 months, surging from round 2.63p, all the best way to 11p! And now that its market-cap has surged past the £100m threshold, the enterprise has developed from a distinct segment penny inventory right into a rising pharmaceutical small-cap – a tough and spectacular feat.
However what precipitated all this? Why has the share value erupted over the previous yr, and will I be including this enterprise to my portfolio as we speak?
What’s behind the share value surge?
Protect Therapeutics is a speciality commercial-stage pharma enterprise centered on iron deficiency therapies and is the mastermind behind ACCRUFeR.
Whereas ACCRUFeR isn’t a family title, the drug’s the primary and at the moment solely FDA-approved oral iron product that targets each iron deficiency and iron deficiency anaemia – one thing that over 20m folks within the US endure from. And simply final month, the FDA prolonged approval for adolescents following constructive outcomes from section three paediatric medical trials.
The mix of regulatory approvals, widespread demand, and superior efficacy versus generic dietary supplements has translated into spectacular income progress. Within the third quarter of 2025, the whole variety of energetic ACCRUFeR subscriptions reached 54,000, producing $13.1m in internet income – an 82% year-on-year enhance.
Regardless of barely scratching the floor of its goal market, the enterprise is already on the verge of turning free money circulate constructive in 2026. And with losses shrinking quickly, earnings are anticipated to observe as of 2027. And so it’s not stunning to see Protect Therapeutics’ share value surge on this essential inflexion level milestone.
Bull and bear circumstances
So 2026 appears to be like to be an thrilling yr for this pharma enterprise. Protect Therapeutics has a first-mover benefit in a worldwide market valued at round $5.6bn, on monitor to develop to $10.9bn by 2034. And the current paediatric regulatory approval has solely accelerated its trajectory, with comparable approval anticipated in Europe later this yr.
Combining this momentum with the expectation of constructive free money flows, the group’s danger profile has considerably been adjusted downward. Nevertheless, that doesn’t imply Protect Therapeutics is a slam-dunk purchase.
The enterprise is nearly fully depending on ACCRUFeR for its revenues, creating substantial single-product danger. If manufacturing is disrupted, a competing product enters the market, or medical health insurance firms refuse to cowl the drug, income progress may grow to be handicapped in a short time.
That’s notably harmful given the group’s continued money burn price. Its newest quarterly outcomes present administration nonetheless has $8.6m of money & equivalents on its steadiness sheet as of final September. However that’s down from $10.8m in June. Subsequently, if progress slows and consequently free money circulate era fails to show constructive, the corporate may very well be compelled to boost capital, probably by fairness.
Time to purchase?
There’s rather a lot to be enthusiastic about when this enterprise with a compelling bull case and ample room for substantial progress. Nevertheless, there’s no denying the heightened diploma of execution danger and restricted monetary margin of error.
It’s a traditional high-risk/high-reward pharma inventory. However with the corporate having already overcome the big challenges and limitations to pharma trade entry, I believe Protect Therapeutics is certainly worthy of nearer inspection for traders snug with volatility.
